Chronic bronchitis and emphysema (chronic obstructive pulmonary disease [COPD])
represent a major health problem in this country. Corticosteroids have provided an important …

Inhaled corticosteroids (ICS) are important in reducing exacerbation frequency associated
with chronic obstructive pulmonary disease (COPD). However, little is known about the risk …

Background Guidelines recommend inhaled corticosteroids (ICS) for patients with severe
chronic obstructive pulmonary disease (COPD). Most COPD patients are managed in …

The aim of this study was to investigate whether inhaled corticosteroid (ICS) use affects
outcome in patients with chronic obstructive pulmonary disease (COPD) admitted with …

Long-term treatment with inhaled corticosteroids (ICS) might attenuate lung function decline
and decrease airway inflammation in a subset of patients with chronic obstructive pulmonary …

INTRODUCTION: The use of inhaled corticosteroids (ICS) in COPD may be associated with
an increased risk of pneumonia. Little is known of this risk in newly diagnosed COPD …

Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in
health related quality of life but have little effect on lung function, do not reduce mortality, and …

Inhaled corticosteroids (ICSs) treatment combined with long-acting β2-adrenoceptor
agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is …

The role of inhaled corticosteroids (ICS) in asthma is well established, but their benefit in the
management of chronic obstructive pulmonary disease (COPD) is still controversial. The …

Background Treatment with inhaled glucocorticoids in combination with long-acting
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …